UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 8, 2003
BioReliance Corporation
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
| | | |
0-22879
(Commission File Number) | | 52-1541583
(IRS Employer Identification No.) |
| | | |
14920 Broschart Road
Rockville, Maryland
(Address of principal executive offices) | | 20850
(Zip Code) |
Registrant’s telephone number, including area code: (301) 738-1000
Not Applicable
(Former name or former address, if changed since last report)
Item 7. Financial Statements and Exhibits
(c) Exhibits
The following exhibit is furnished pursuant to Item 9:
99.1 Press Release dated December 8, 2003.
Item 9. Regulation FD Disclosure
On December 8, 2003, BioReliance Corporation issued a press release regarding the anticipated cost synergies in connection with the acquisition of Q-One Biotech Group, Ltd. The press release is furnished as Exhibit 99.1 hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | |
| | | | | BIORELIANCE CORPORATION | | |
| |
| | | By: | | /s/ John L. Coker
John L. Coker
Senior Vice President, Finance and
Administrative & Chief Financial
Officer | | |
| |
| Date: December 8, 2003 | | | | | | |
